James R. Kasinger

Companies

• CRISPR TherapeuticsGeneral counsel Jun 1, 2017 to now¹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• CRISPR Therapeutics CRSP94,784 shares²$4.7M at $49.91Sep 22, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Sep 22, 2026Sold 10,400 shares at $60.24 of CRISPR Therapeutics²
• Sep 22, 2026Exercised options 10,400 shares at $13.62 of CRISPR Therapeutics²
• Mar 23, 2026Sold 3,182 shares at $46.78 of CRISPR Therapeutics³
• Mar 20, 2026Exercised options 6,250 shares of CRISPR Therapeutics³
• Mar 16, 2026Sold 3,450 shares at $48.26 of CRISPR Therapeutics⁴
• Mar 14, 2026Exercised options 6,875 shares of CRISPR Therapeutics⁴
• Mar 11, 2026Sold 2,800 shares at $52.80 of CRISPR Therapeutics⁵
• Mar 10, 2026Exercised options 5,500 shares of CRISPR Therapeutics⁵
• Feb 19, 2026Sold 2,112 shares at $52.58 of CRISPR Therapeutics⁶
• Feb 18, 2026Exercised options 3,825 shares of CRISPR Therapeutics⁶
• Oct 14, 2025Sold 1,076 shares at $66.60 of CRISPR Therapeutics⁷
• Oct 13, 2025Exercised options 2,114 shares of CRISPR Therapeutics⁷
• Mar 21, 2025Sold 3,185 shares at $41.23 of CRISPR Therapeutics⁸
• Mar 20, 2025Exercised options 6,250 shares of CRISPR Therapeutics⁸
• Mar 12, 2025Sold 1,116 shares at $43.32 of CRISPR Therapeutics⁹
• Mar 11, 2025Exercised options 2,250 shares of CRISPR Therapeutics⁹
• Mar 11, 2025Sold 2,850 shares at $42.42 of CRISPR Therapeutics⁹
• Mar 10, 2025Exercised options 5,500 shares of CRISPR Therapeutics⁹
• Feb 19, 2025Sold 1,947 shares at $52.80 of CRISPR Therapeutics¹⁰
• Feb 18, 2025Exercised options 3,825 shares of CRISPR Therapeutics¹⁰
• Feb 18, 2025Sold 9,595 shares at $53.85 of CRISPR Therapeutics¹⁰
• Feb 16, 2025Exercised options 20,000 shares of CRISPR Therapeutics¹⁰
• Oct 14, 2024Sold 1,089 shares at $46.28 of CRISPR Therapeutics¹¹
• Oct 13, 2024Exercised options 2,113 shares of CRISPR Therapeutics¹¹
• Mar 12, 2024Sold 1,146 shares at $74.44 of CRISPR Therapeutics¹²